Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AR-17043 + latanoprost
- Development stage
- Unknown
- Lead developer
- Alcon
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
AR-17043 + latanoprost is a fixed-dose combination ophthalmic solution being developed for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. **AR-17043** is an investigational ophthalmic agent, currently in Phase 2 trials. Its precise mechanism of action has not been explicitly disclosed in available sources, but as a new-generation candidate in a therapeutic area with precedent (such as netarsudil or other ROCK inhibitors), it likely targets pathways involved in aqueous humor outflow (potentially Rho-associated protein kinase inhibition, though this is not confirmed). **Latanoprost** is a prostaglandin F2-alpha analog that selectively stimulates prostaglandin F2 alpha receptors to increase uveoscleral outflow, thereby lowering intraocular pressure. The combination aims to provide additive or synergistic IOP-lowering effects for enhanced control in glaucoma or ocular hypertension[1][2].
- Other names
- AR-17043 + latanoprost
02
Targets
PTGFR (Prostaglandin F2 alpha receptor)ROCK1 (Rho-associated coiled-coil containing protein kinase 1)
Beyond the preview
Go deeper on AR-17043 + latanoprost.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AR-17043 + latanoprost.